These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23738665)

  • 1. Targeting drug delivery systems for circumventing multidrug resistance of cancers.
    Ju RJ; Mu LM; Lu WL
    Ther Deliv; 2013 Jun; 4(6):667-71. PubMed ID: 23738665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.
    Yu Y; Wang ZH; Zhang L; Yao HJ; Zhang Y; Li RJ; Ju RJ; Wang XX; Zhou J; Li N; Lu WL
    Biomaterials; 2012 Feb; 33(6):1808-20. PubMed ID: 22136714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer.
    Zhou J; Zhao WY; Ma X; Ju RJ; Li XY; Li N; Sun MG; Shi JF; Zhang CX; Lu WL
    Biomaterials; 2013 May; 34(14):3626-38. PubMed ID: 23422592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.
    Malam Y; Loizidou M; Seifalian AM
    Trends Pharmacol Sci; 2009 Nov; 30(11):592-9. PubMed ID: 19837467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
    Li N; Zhang CX; Wang XX; Zhang L; Ma X; Zhou J; Ju RJ; Li XY; Zhao WY; Lu WL
    Biomaterials; 2013 Apr; 34(13):3366-80. PubMed ID: 23410681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance.
    Wang F; Zhang D; Zhang Q; Chen Y; Zheng D; Hao L; Duan C; Jia L; Liu G; Liu Y
    Biomaterials; 2011 Dec; 32(35):9444-56. PubMed ID: 21903258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells.
    Wang XX; Li YB; Yao HJ; Ju RJ; Zhang Y; Li RJ; Yu Y; Zhang L; Lu WL
    Biomaterials; 2011 Aug; 32(24):5673-87. PubMed ID: 21550109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
    Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
    J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the cancer stem cell population "a player" in multi-drug resistance?
    Drewa T; Styczynski J; Szczepanek J
    Acta Pol Pharm; 2008; 65(4):493-500. PubMed ID: 19051593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in the study of micelle delivery system reversing multidrug resistance].
    Diao YY; Han M; Chen DW; Gao JQ
    Yao Xue Xue Bao; 2009 Jul; 44(7):710-5. PubMed ID: 19806907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells.
    Zhang L; Yao HJ; Yu Y; Zhang Y; Li RJ; Ju RJ; Wang XX; Sun MG; Shi JF; Lu WL
    Biomaterials; 2012 Jan; 33(2):565-82. PubMed ID: 21983136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles.
    Pan L; Liu J; He Q; Wang L; Shi J
    Biomaterials; 2013 Apr; 34(11):2719-30. PubMed ID: 23337327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor.
    Yin Q; Shen J; Zhang Z; Yu H; Li Y
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1699-715. PubMed ID: 23611952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention.
    Harasym TO; Liboiron BD; Mayer LD
    Methods Mol Biol; 2010; 596():291-323. PubMed ID: 19949929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Particle carriers for combating multidrug-resistant cancer.
    Yan Y; Björnmalm M; Caruso F
    ACS Nano; 2013 Nov; 7(11):9512-7. PubMed ID: 24215340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combating apoptosis and multidrug resistant cancers by targeting lysosomes.
    Groth-Pedersen L; Jäättelä M
    Cancer Lett; 2013 May; 332(2):265-74. PubMed ID: 20598437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
    Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer.
    Hu CM; Zhang L
    Biochem Pharmacol; 2012 Apr; 83(8):1104-11. PubMed ID: 22285912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.